Glaukos Corp
Închisă
SectorSănătate
126.95 -0.48
Rezumat
Modificarea prețului
24h
Minim
126.18
Maxim
131.51
Venit | 114M -20M |
|---|---|
Vânzări | 7.5M 151M |
EPS | -0.18 |
Marjă de profit | -13.139 |
Angajați | 1,094 |
EBITDA | 124M -5.3M |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +23.5% upside |
Următoarele câștiguri | 29 iul. 2026 |
|---|
Capitalizare de piață | 487M 7.6B |
|---|---|
Deschiderea anterioară | 127.43 |
Închiderea anterioară | 126.95 |
Sentimentul știrilor
By Acuity
42%
58%
138 / 342 Clasament în Healthcare
Glaukos Corp Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.